Treatment of neuromyelitis optica: an evidence based review
Open Access
- 1 January 2012
- journal article
- review article
- Published by FapUNIFESP (SciELO) in Arquivos de Neuro-Psiquiatria
- Vol. 70 (1), 59-66
- https://doi.org/10.1590/s0004-282x2012000100012
Abstract
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system characterized by severe optic neuritis and transverse myelitis, usually with a relapsing course. Aquaporin-4 antibody is positive in a high percentage of NMO patients and it is directed against this water channel richly expressed on foot processes of astrocytes. Due to the severity of NMO attacks and the high risk for disability, treatment should be instituted as soon as the diagnosis is confirmed. There is increasing evidence that NMO patients respond differently from patients with multiple sclerosis (MS), and, therefore, treatments for MS may not be suitable for NMO. Acute NMO attacks usually are treated with high dose intravenous corticosteroid pulse and plasmapheresis. Maintenance therapy is also required to avoid further attacks and it is based on low-dose oral corticosteroids and non-specific immunosuppressant drugs, like azathioprine and mycophenolate mofetil. New therapy strategies using monoclonal antibodies like rituximab have been tested in NMO, with positive results in open label studies. However, there is no controlled randomized trial to confirm the safety and efficacy for the drugs currently used in NMO.Keywords
This publication has 50 references indexed in Scilit:
- Antibody to aquaporin-4 in the long-term course of neuromyelitis opticaBrain, 2008
- Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysisMultiple Sclerosis Journal, 2007
- Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titreBrain, 2007
- Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis opticaMultiple Sclerosis Journal, 2007
- Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 ExpressionArchives of Neurology, 2006
- Revised diagnostic criteria for neuromyelitis opticaNeurology, 2006
- Grading Strength of Recommendations and Quality of Evidence in Clinical GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosisThe Lancet, 2004
- The clinical course of neuromyelitis optica (Devic’s syndrome)Neurology, 1999
- Devic's neuromyelitis optica: A prospective study of seven patients treated with prednisone and azathioprineNeurology, 1998